The medication is generally used for the relief of occasional sleeplessness when associated with minor aches and pains.

“This combination is often used when groups of symptoms create noticeable functional strain during rest.”

The primary focus is the simultaneous support for easing symptoms related to physical discomfort and the occasional inability to rest that may result. The analgesic component is relevant for easing symptoms related to localized discomfort, such as headache, backache, muscular aches, and minor pain of arthritis. This combination is applied in clinical settings that involve acute, non-frequent symptom patterns, contributing to easing the overall symptom burden and supporting the patient during difficult episodes by easing distress.

---

Quick Fact: Management of Occasional Sleep Disruption

Aleve PM, which combines the NSAID naproxen sodium and the antihistamine diphenhydramine hydrochloride, is intended for adults and children 12 years of age and older to treat occasional sleeplessness coupled with minor aches or pains. It is not indicated for treating sleeplessness alone.

Contraindications and Cautions

Certain individuals should not use this product due to increased health risks or potential drug interactions. Use is contraindicated if you have:

• A history of allergic reaction to naproxen, diphenhydramine, aspirin, or any other nonsteroidal anti-inflammatory drug (NSAID).
• Are undergoing or have recently undergone heart bypass surgery (CABG).
• Have had a recent stomach or intestinal bleed or active peptic ulcer disease.
• Are in the last trimester of pregnancy (20 weeks or later), as naproxen can harm the fetus and cause delivery complications.

Consult a healthcare professional before use if you have: a history of heart attack or stroke, high blood pressure, liver or kidney disease, a bleeding disorder, asthma, glaucoma, or trouble urinating due to an enlarged prostate. Additionally, caution is advised if taking anticoagulants, steroids, or other sedating medications.

The official regulatory interaction profile for this product is defined by documented risks associated with its two active components, naproxen sodium and diphenhydramine.

Pharmacodynamic Interaction Constraints

The co-administration of this product with specific medicinal classes and substances is officially restricted due to additive clinical effects:

• Bleeding Risk: The risk of severe gastrointestinal bleeding is increased when taken concurrently with other nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin and ibuprofen, as well as with blood-thinning (anticoagulant) drugs or steroid medications (corticosteroids).
• Central Nervous System (CNS) Depression: Official labeling warns that the consumption of alcohol, sedatives, tranquilizers, or other sleep-aids may lead to additive drowsiness and increased CNS effects due to the diphenhydramine component.
• Aspirin Interference: Naproxen may decrease the benefit of low-dose aspirin when it is taken for the prevention of heart attack or stroke, requiring consultation prior to co-administration.

Other Co-Administration Requirements

Regulatory information states that this product should not be used with any other product containing diphenhydramine, even those used on the skin. Furthermore, while food does not significantly affect the total amount of naproxen absorbed, taking the product with food or milk may result in a delay in the time it takes to begin working.

How Aleve PM Works

Aleve PM initiates distinct biochemical cascades through two separate mechanistic domains.

Enzymatic Inhibition of Prostaglandin Synthesis

The naproxen sodium component acts by limiting the activity of cyclooxygenase (COX) enzymes. This mechanism targets the eicosanoid pathway to reduce the production of prostaglandins, which are chemical mediators that modulate nerve sensitivity and inflammatory processes. This targeted enzyme interference limits the impact of prostaglandin synthesis on peripheral signaling and inflammatory responses.

Central Nervous System Histamine mathbfH1 Receptor Antagonism

The diphenhydramine HCl component works by antagonizing histamine H1 receptors within the central nervous system (CNS). By blocking the activity of the histaminergic system, which is essential for maintaining alertness, this mechanism initiates a cascade that dampens the body's natural arousal state. This action supports a regulated and temporary reduction in CNS activity, which contributes to the development of somnolence (drowsiness).

How to use Aleve PM — Official Administration Guidelines

The administration of the Aleve PM fixed-dose combination is standardized by administration guidelines, specifying the route, dose, frequency, and timing of intake. The product is an oral medication, typically a caplet or tablet.

---

Administration Scope

The labeled dose for a single administration is mathbftwo caplets. This dose delivers mathbf440 mg Naproxen Sodium and mathbf50 mg Diphenhydramine Hydrochloride. The official dosing regimen is mathbfonce daily, and administration is precisely timed to occur mathbfat bedtime. A strict restriction on usage is that intake must not exceed mathbftwo caplets within a mathbf24-hour period.

The dose must be administered with a mathbffull glass of water. It is also noted that administering the caplets concurrently with food may prolong the time required for the drug to provide its effect.

---

Age-Group Administration Rules

The medication is authorized for use in individuals mathbf12 years of age and older, which reflects the specific age-group administration rule. For children under 12, the use of this fixed-dose combination product is not specified or established in official documentation. The use pattern is designated for short-term, mathbfas needed (PRN) administration.

---

Connection to the Overall Use Protocol

The official administration protocol establishes the unvarying, standardized dose and strictly governs its use to a once-daily, at-bedtime schedule. These procedural constraints define a singular, standardized use pattern based on the fixed-dose ratio and the maintenance of the required 24-hour interval between administrations.

Research evidence / Overview of Studies for Aleve PM

The Core Research Question and Study Design

Research examined the combination of two ingredients: naproxen sodium, an NSAID, and diphenhydramine hydrochloride, a sedating antihistamine. Studies explored the dual formulation's relevance in trials assessing short-term, acute symptom patterns associated with occasional sleeplessness.

To explore this, the evidence landscape includes multiple short-term, randomized controlled trials (RCTs). These studies were typically double-blind, comparing the combination against a placebo and against each of the active ingredients taken alone. Research also describes pharmacokinetic (PK) studies, which monitored how the two ingredients were absorbed when administered together.

---

Evidence for Use in Occasional Sleeplessness Associated with Minor Aches and Pains

Research was studied for use in clinical situations characterized by acute, temporary discomfort that affects rest. The main efficacy studies were evaluated in controlled research settings involving generally healthy adults and adolescents. This postsurgical dental pain model was used in research exploring short-term symptom changes in subjects who presented with acute pain, a strategy used to model occasional sleeplessness.

The studies monitored outcomes related to both physical discomfort and systemic or functional imbalance leading to sleeplessness. Findings describe patterns observed in the studies related to outcomes monitoring physiological strain or stress and pain intensity. For instance, some trials described patterns where the fixed-dose combination data show patterns related to smaller measured changes in both the time to fall asleep and the time spent awake when measured against the naproxen sodium component or placebo groups.

---

What Remains Uncertain in the Research Landscape

The evidence base, while relying on RCTs, contains limitations that contribute to uncertainty. The primary research was conducted using a very specific and highly controlled model—the postsurgical dental pain setting. These study results reflect the specific conditions under which they were conducted, and results apply only to the populations studied regarding other forms of minor aches and pains. Furthermore, regulatory reviews noted that inconsistent results were observed across some co-primary sleep outcomes for certain strengths of the fixed-dose combination. The evidence for effect is established mainly based on single-dose studies, and follow-up durations were limited, meaning long-term effects are not well characterized. Data for groups such as older adults remain insufficient.

Common questions about Aleve PM (FAQ)

Q: Is Aleve PM the same as prescription sleep aids?

A: Aleve PM is an over-the-counter (OTC) combination product containing naproxen sodium (a pain reliever) and diphenhydramine (a sleep aid). Prescription sleep aids often contain different active ingredients and are regulated differently. It is important to confirm with a healthcare provider whether an OTC option is appropriate for your needs.

Q: How long can I take Aleve PM for pain and sleeplessness?

A: The duration of use for Aleve PM should be limited. Diphenhydramine, the sleep aid component, is typically intended for short-term use to treat occasional sleeplessness. Using naproxen sodium for long periods requires guidance from a healthcare professional, as prolonged use of NSAIDs can increase risks of certain side effects.

Q: Should I avoid certain foods or beverages while taking Aleve PM?

A: It is generally recommended to avoid consuming alcohol while taking Aleve PM, as alcohol can increase the sedative effects of the diphenhydramine component. You should also be cautious with other products that contain nonsteroidal anti-inflammatory drugs (NSAIDs) to avoid exceeding recommended limits.

Q: Can Aleve PM cause rebound insomnia?

A: Rebound insomnia is a potential concern when discontinuing some medications used for sleep. While Aleve PM is intended for short-term use, if you have difficulty sleeping after stopping it, it is advisable to consult a healthcare provider.

The official labeling for Aleve PM (naproxen sodium and diphenhydramine HCl) mandates specific storage conditions to maintain its stability and integrity.

Storage Requirements

• Temperature: Store the product at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F).
• Protection: Avoid excessive heat above 40 C (104 F) and high humidity.
• Container: The labeling instructs the user to keep the outer carton for storage.
• Safety: As a required measure, the medication must be stored out of reach of children.

Disposal

The product's official labeling does not contain specific disposal instructions. Unused or expired medication should be discarded following general governmental guidelines, which recommend using a drug take-back program or mixing the drug with an undesirable substance before disposal in household trash.